Company* |
Company |
Type/Product Area | Terms/Details (Date) |
| | |||
Avant Immuno- |
Paul Royalty | Paul Royalty purchased an interest in royalties Avant will receive from sales of Rotarix by GlaxoSmithKline plc | Avant gets $10M and would get $40M upon product launch in Europe and about $10M upon launch in the U.S.; Avant also retained an interest in royalties from the product, which is used against rotavirus infections (5/18) |
Diversa Corp. |
Bio Integration Technology Inc. (China) |
Collaboration to identify opportunities for Diversa's enzyme products in the Chinese oil and gas industry |
Terms of the deal were not disclosed (4/25) |
Geneva |
Hitachi Software Enginerring Co. Ltd. (Japan) |
Hitachi will distribute GeneBio's Phenyx software platform in the Japanese market |
The platform is used to identify and characterize proteins and peptides from mass spectrometry data; terms of the deal were not disclosed (6/2) |
Genaissance Pharmaceuticals |
INC |
Genaissance will provide pharmacogenetic clinical development services to clients of INC |
INC is a contract research organization; terms of the deal were not disclosed (6/7) |
LineaGen Research |
IBM |
Collaboration to create a clinical genomics infrastructure designed to accelerate the molecular understanding of complex diseases |
IBM initially will integrate Utah population databases into its Clinical Genomics Solution; future phases will center on development of tools to support molecular models of genetic disease (5/18) |
PharmaFrontiers |
INC |
Deal under which INC will manage PharmaFrontiers' multiple sclerosis development program |
INC is a contract research organization; PharmaFrontiers' MS product Tovaxin is moving into Phase II trials; terms of the deal were not disclosed (5/3) |
Senomyx Inc. |
Kraft Foods Global Inc. | They extended the research phase of their collaboration to discover flavor modifiers in the dessert category |
The deal was extended to July 30, 2005; Senomyx gets research funding and is entitled to royalties on any resulting sales (5/2) |
Spectrum Pharmaceuticals |
Robert E. |
Spectrum acquired rights to lucanthone, a radiation sensitizer in Phase II trials |
Bases is inventor of a method of treating cancer of the central nervous system through the administration of lucanthone and radiation; terms were not disclosed (5/17) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
OTC BB = Over-the-Counter Bulletin Board. | |||
To read more on related topics, click on one of the words below.